ReviewFrontiers in cardiovascular medicine2021
Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Exercise-based interventions for preventing and treating cancer therapy-related cardiovascular toxicity: a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- The gut-heart axis in cardio-oncology.Cardiovascular research · 2026Review
- Impact of cancer history on coronary calcification and clinical outcomes in intravascular ultrasound-guided percutaneous coronary intervention.Coronary artery disease · 2026Article
- Ischemic heart disease and cardio-onco-hematology: a comprehensive review.Cardio-oncology (London, England) · 2026Review
- Molecular regulators of thromboinflammation and angiogenesis in pediatric cancer: emerging roles of noncoding RNAs, epigenetics, and extracellular vesicles - narrative review.Annals of medicine and surgery (2012) · 2026Review
- In Vivo Extracellular Recording Reveals Bidirectional Changes in Neuronal Activity in the Rat Spinal Dorsal Horn After Hindlimb Ischemia-Reperfusion.International journal of molecular sciences · 2026Article
- Sensor Monitoring of Thermal and Vascular Changes During Neoadjuvant Treatment.Sensors (Basel, Switzerland) · 2026Article
- Automating Vascular Biology: An End-to-End Automated Workflow for High-Throughput Blood Vessel-on-a-Chip Production and Multi-Site Validation.Advanced healthcare materials · 2026Article
- Chemotherapy-associated coronary thrombosis presenting as acute coronary syndrome in breast cancer: a case report.BMC cardiovascular disorders · 2026Article
- Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management.Frontiers in pharmacology · 2026Review
- The multidimensional roles and mechanisms of exercise intervention in pediatric oncology.Frontiers in immunology · 2026Review
- Development and validation of a competing risk nomogram for predicting PICC-related venous thrombosis in patients with gastrointestinal malignancies.Frontiers in oncology · 2026Article
- Trajectories of fatigue-pain-sleep disturbance symptom cluster in patients with lung cancer undergoing chemotherapy and its predictive factors: Latent class growth model.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Frequency of ischemic cardiac events in patients receiving long-term multikinase inhibitor: A report of three cases.Asia-Pacific journal of oncology nursing · 2025Article
- The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose.FEBS letters · 2025Article
- Cancer therapy-induced cardiotoxicity: mechanisms and mitigations.Heart failure reviews · 2025Review
- Correlation of enlarged perivascular spaces in basal ganglion and cancer-associated stroke: a case-control study in China.Stroke and vascular neurology · 2025Article
- Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy.Journal of clinical medicine · 2025Review
- Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.Clinical science (London, England : 1979) · 2024Article
- Exploring Extravasation in Cancer Patients.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular toxicity is a frequent adverse effect of current anticancer chemotherapies and often results from endothelial dysfunction. Vascular endothelial growth factor inhibitors (VEGFi), anthracyclines, plant alkaloids, alkylating agents, antimetabolites, and radiation therapy evoke vascular toxicity. These anticancer treatments not only affect tumor vascularization in a beneficial manner, they also damage ECs in the heart. Cardiac ECs have a vital role in cardiovascular functions including hemostasis, inflammatory and coagulation responses, vasculogenesis, and angiogenesis. EC damage can be resulted from capturing angiogenic factors, inhibiting EC proliferation, survival and signal transduction, or altering vascular tone. EC dysfunction accounts for the pathogenesis of myocardial infarction, atherothrombosis, microangiopathies, and hypertension. In this review, we provide a comprehensive overview of the effects of chemotherapeutic agents on vascular toxicity leading to hypertension, microvascular rarefaction thrombosis and atherosclerosis, and affecting drug delivery. We also describe the potential therapeutic approaches such as vascular endothelial growth factor (VEGF)-B and prokineticin receptor-1 agonists to maintain endothelial function during or following treatments with chemotherapeutic agents, without affecting anti-tumor effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.